Neuberger Berman Group
ARCT icon

Neuberger Berman Group’s Arcturus Therapeutics ARCT Stock Holding History

Neuberger Berman Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-82,546
Closed -$2.79M – 1901
2024
Q1 		$2.79M Buy
+82,546
New +$2.92M ﹤0.01% 1049

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Neuberger Berman Group's ARCT Position: Q2 2024 in Review

Neuberger Berman Group sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 82,546 shares — an estimated $2.79M sold.

Neuberger Berman Group first reported a position in ARCT in Q1 2024 and held it in 1 quarter. The position peaked at $2.79M in Q1 2024. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Neuberger Berman Group reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 82,546 Arcturus Therapeutics shares in Q2 2024, an estimated $2.79M.
  • Neuberger Berman Group first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Neuberger Berman Group's Arcturus Therapeutics position peaked at $2.79M in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Neuberger Berman Group's 13F filing for Q2 2024, filed 13 Aug 2024.